Business costs have been increasing at the BBLG in the most recent fiscal period

As the earnings season of the July to September 30 2022 resumes, many entities have announced their results. In the thick of it, are various constituents of the Medical Equipment & Supplies industry. And now, BBLG disclosed operating deficit of $-1.219277 millions, for the third quarter of 2022 earnings season.

The operating deficit has contracted from $-0.229789 millions, from the third quarter of 2021. But more importantly, the investors are ruminating, when the BBLGs' may start to report the top-line.


The crucial observation in most recent fiscal period, next to the absence of top-line, has been a $-1.219 millions net loss, as it has enlarged significantly from $-0.509 millions, compared to the same period a year before.


Bone Biologics Corporation is expected to report next financial recent numbers on March 14, 2023.